Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Dapporto F, Marchi S, Leonardi M, Piu P, Lovreglio P, Decaro N, Buonvino N, Stufano A, Lorusso E, Bombardieri E, Ruello A, Viviani S, Molesti E, Trombetta CM, Manenti A, Montomoli E, Passero LF. Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination. J Immunol Res 2022;2022:1-9. [PMID: 36093434 PMCID: PMC9453088 DOI: 10.1155/2022/4813199] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2022] [Accepted: 08/08/2022] [Indexed: 01/11/2023] Open

For:	Dapporto F, Marchi S, Leonardi M, Piu P, Lovreglio P, Decaro N, Buonvino N, Stufano A, Lorusso E, Bombardieri E, Ruello A, Viviani S, Molesti E, Trombetta CM, Manenti A, Montomoli E, Passero LF. Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination. J Immunol Res 2022;2022:1-9. [PMID: 36093434 PMCID: PMC9453088 DOI: 10.1155/2022/4813199] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2022] [Accepted: 08/08/2022] [Indexed: 01/11/2023] Open

Number

Cited by Other Article(s)

Portilho AI, Hermes Monteiro da Costa H, Grando Guereschi M, Prudencio CR, De Gaspari E. Hybrid response to SARS-CoV-2 and Neisseria meningitidis C after an OMV-adjuvanted immunization in mice and their offspring. Hum Vaccin Immunother 2024;20:2346963. [PMID: 38745461 DOI: 10.1080/21645515.2024.2346963] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2023] [Accepted: 04/20/2024] [Indexed: 05/16/2024] Open

Mallory M, Munt JE, Narowski TM, Castillo I, Cuadra E, Pisanic N, Fields P, Powers JM, Dickson A, Harris R, Wargowsky R, Moran S, Allabban A, Raphel K, McCaffrey TA, Brien JD, Heaney CD, Lafleur JE, Baric RS, Premkumar L. COVID-19 point-of-care tests can identify low-antibody individuals: In-depth immunoanalysis of boosting benefits in a healthy cohort. SCIENCE ADVANCES 2024;10:eadi1379. [PMID: 38865463 PMCID: PMC11168476 DOI: 10.1126/sciadv.adi1379] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/05/2023] [Accepted: 05/08/2024] [Indexed: 06/14/2024]

Affiliation(s)

Michael Mallory Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, NC, USA Department of Epidemiology, UNC Chapel Hill School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Jennifer E. Munt Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, NC, USA Department of Epidemiology, UNC Chapel Hill School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Tara M. Narowski Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, NC, USA
Izabella Castillo Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, NC, USA
Edwing Cuadra Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, NC, USA
Nora Pisanic Department of Environmental Health and Engineering, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
Paul Fields Adaptive Biotechnologies, Seattle, WA, USA
John M. Powers Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, NC, USA Department of Epidemiology, UNC Chapel Hill School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Alexandria Dickson Department of Molecular Microbiology and Immunology, Saint Louis University, Saint Louis, MO, USA
Rohan Harris Department Emergency Medicine, George Washington University School of Medicine, Washington, DC, USA
Richard Wargowsky Department of Medicine, Division of Genomic Medicine, The George Washington University Medical Center, Washington, DC, USA
Seamus Moran Department Emergency Medicine, George Washington University School of Medicine, Washington, DC, USA
Ahmed Allabban Department Emergency Medicine, George Washington University School of Medicine, Washington, DC, USA
Kristin Raphel Department Emergency Medicine, George Washington University School of Medicine, Washington, DC, USA
Timothy A. McCaffrey Department of Medicine, Division of Genomic Medicine, The George Washington University Medical Center, Washington, DC, USA
James D. Brien Department of Molecular Microbiology and Immunology, Saint Louis University, Saint Louis, MO, USA
Christopher D. Heaney Department of Environmental Health and Engineering, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA Department of International Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA
John E. Lafleur Department Emergency Medicine, George Washington University School of Medicine, Washington, DC, USA
Ralph S. Baric Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, NC, USA Department of Epidemiology, UNC Chapel Hill School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Lakshmanane Premkumar Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, NC, USA

Collapse

Bullock JL, Hickey TE, Kemp TJ, Metz J, Loftus S, Haynesworth K, Castro N, Luke BT, Lowy DR, Pinto LA. Longitudinal Assessment of BNT162b2- and mRNA-1273-Induced Anti-SARS-CoV-2 Spike IgG Levels and Avidity Following Three Doses of Vaccination. Vaccines (Basel) 2024;12:516. [PMID: 38793767 PMCID: PMC11125776 DOI: 10.3390/vaccines12050516] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2024] [Revised: 04/24/2024] [Accepted: 05/02/2024] [Indexed: 05/26/2024] Open

Affiliation(s)

Jimmie L. Bullock Vaccine, Immunity and Cancer Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA; (J.L.B.J.); (T.E.H.); (T.J.K.); (J.M.); (S.L.); (K.H.)
Thomas E. Hickey Vaccine, Immunity and Cancer Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA; (J.L.B.J.); (T.E.H.); (T.J.K.); (J.M.); (S.L.); (K.H.)
Troy J. Kemp Vaccine, Immunity and Cancer Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA; (J.L.B.J.); (T.E.H.); (T.J.K.); (J.M.); (S.L.); (K.H.)
Jordan Metz Vaccine, Immunity and Cancer Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA; (J.L.B.J.); (T.E.H.); (T.J.K.); (J.M.); (S.L.); (K.H.)
Sarah Loftus Vaccine, Immunity and Cancer Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA; (J.L.B.J.); (T.E.H.); (T.J.K.); (J.M.); (S.L.); (K.H.)
Katarzyna Haynesworth Vaccine, Immunity and Cancer Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA; (J.L.B.J.); (T.E.H.); (T.J.K.); (J.M.); (S.L.); (K.H.)
Nicholas Castro Vaccine, Immunity and Cancer Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA; (J.L.B.J.); (T.E.H.); (T.J.K.); (J.M.); (S.L.); (K.H.)
Brian T. Luke Bioinformatics and Computational Science Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA;
Douglas R. Lowy Laboratory of Cellular Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA;
Ligia A. Pinto Vaccine, Immunity and Cancer Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA; (J.L.B.J.); (T.E.H.); (T.J.K.); (J.M.); (S.L.); (K.H.)

Collapse

Golding L, Watts AW, Shew J, Viñeta Paramo M, Mâsse LC, Goldfarb DM, Abu-Raya B, Lavoie PM. A Novel Anti-nucleocapsid Antibody Avidity Method for Identifying SARS-CoV-2 Reinfections. J Infect Dis 2024:jiae072. [PMID: 38442331 DOI: 10.1093/infdis/jiae072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2023] [Accepted: 02/07/2024] [Indexed: 03/07/2024] Open

Affiliation(s)

Liam Golding British Columbia Children's Hospital Research Institute, University of British Columbia, Vancouver, British Columbia, Canada Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
Allison W Watts British Columbia Children's Hospital Research Institute, University of British Columbia, Vancouver, British Columbia, Canada
Jacob Shew British Columbia Children's Hospital Research Institute, University of British Columbia, Vancouver, British Columbia, Canada Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
Marina Viñeta Paramo British Columbia Children's Hospital Research Institute, University of British Columbia, Vancouver, British Columbia, Canada Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada Women+ and Children's Health, Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada
Louise C Mâsse British Columbia Children's Hospital Research Institute, University of British Columbia, Vancouver, British Columbia, Canada School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada
David M Goldfarb British Columbia Children's Hospital Research Institute, University of British Columbia, Vancouver, British Columbia, Canada Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada
Bahaa Abu-Raya British Columbia Children's Hospital Research Institute, University of British Columbia, Vancouver, British Columbia, Canada Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
Pascal M Lavoie British Columbia Children's Hospital Research Institute, University of British Columbia, Vancouver, British Columbia, Canada Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada Women+ and Children's Health, Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada

Collapse

Wang S, Guirakhoo F, Periasamy S, Ryan V, Wiggins J, Subramani C, Thibodeaux B, Sahni J, Hellerstein M, Kuzmina NA, Bukreyev A, Dodart JC, Rumyantsev A. RBD-Protein/Peptide Vaccine UB-612 Elicits Mucosal and Fc-Mediated Antibody Responses against SARS-CoV-2 in Cynomolgus Macaques. Vaccines (Basel) 2023;12:40. [PMID: 38250853 PMCID: PMC10818657 DOI: 10.3390/vaccines12010040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2023] [Revised: 12/18/2023] [Accepted: 12/22/2023] [Indexed: 01/23/2024] Open

Affiliation(s)

Shixia Wang Vaxxinity, Inc., Merritt Island, FL 32953, USA; (F.G.); (V.R.); (J.W.); (B.T.); (J.S.); (M.H.); (J.-C.D.)
Farshad Guirakhoo Vaxxinity, Inc., Merritt Island, FL 32953, USA; (F.G.); (V.R.); (J.W.); (B.T.); (J.S.); (M.H.); (J.-C.D.)
Sivakumar Periasamy Department of Pathology, University of Texas Medical Branch, Galveston, TX 77550, USA; (S.P.); (C.S.); (N.A.K.); (A.B.) Galveston National Laboratory, Galveston, TX 77550, USA
Valorie Ryan Vaxxinity, Inc., Merritt Island, FL 32953, USA; (F.G.); (V.R.); (J.W.); (B.T.); (J.S.); (M.H.); (J.-C.D.)
Jonathan Wiggins Vaxxinity, Inc., Merritt Island, FL 32953, USA; (F.G.); (V.R.); (J.W.); (B.T.); (J.S.); (M.H.); (J.-C.D.)
Chandru Subramani Department of Pathology, University of Texas Medical Branch, Galveston, TX 77550, USA; (S.P.); (C.S.); (N.A.K.); (A.B.) Galveston National Laboratory, Galveston, TX 77550, USA
Brett Thibodeaux Vaxxinity, Inc., Merritt Island, FL 32953, USA; (F.G.); (V.R.); (J.W.); (B.T.); (J.S.); (M.H.); (J.-C.D.)
Jaya Sahni Vaxxinity, Inc., Merritt Island, FL 32953, USA; (F.G.); (V.R.); (J.W.); (B.T.); (J.S.); (M.H.); (J.-C.D.)
Michael Hellerstein Vaxxinity, Inc., Merritt Island, FL 32953, USA; (F.G.); (V.R.); (J.W.); (B.T.); (J.S.); (M.H.); (J.-C.D.)
Natalia A. Kuzmina Department of Pathology, University of Texas Medical Branch, Galveston, TX 77550, USA; (S.P.); (C.S.); (N.A.K.); (A.B.) Galveston National Laboratory, Galveston, TX 77550, USA
Alexander Bukreyev Department of Pathology, University of Texas Medical Branch, Galveston, TX 77550, USA; (S.P.); (C.S.); (N.A.K.); (A.B.) Galveston National Laboratory, Galveston, TX 77550, USA Department of Microbiology & Immunology, University of Texas Medical Branch, Galveston, TX 77550, USA
Jean-Cosme Dodart Vaxxinity, Inc., Merritt Island, FL 32953, USA; (F.G.); (V.R.); (J.W.); (B.T.); (J.S.); (M.H.); (J.-C.D.)
Alexander Rumyantsev Vaxxinity, Inc., Merritt Island, FL 32953, USA; (F.G.); (V.R.); (J.W.); (B.T.); (J.S.); (M.H.); (J.-C.D.)

Collapse

Trombetta CM, Marchi S, Leonardi M, Coppola C, Benincasa L, Marotta MG, Buonvino N, Maes P, Stufano A, Pontrelli D, Vasinioti VI, Manenti A, Camero M, Montomoli E, Decaro N, Lovreglio P. Evaluation of immune response to SARS-CoV-2 Omicron sublineages six months after different vaccination regimens in Italy. Acta Trop 2023;248:107042. [PMID: 37863379 DOI: 10.1016/j.actatropica.2023.107042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2023] [Revised: 10/11/2023] [Accepted: 10/17/2023] [Indexed: 10/22/2023]

Harthaller T, Falkensammer B, Bante D, Huber M, Schmitt M, Benainouna H, Rössler A, Fleischer V, von Laer D, Kimpel J, Würzner R, Borena W. Retained avidity despite reduced cross-binding and cross-neutralizing antibody levels to Omicron after SARS-COV-2 wild-type infection or mRNA double vaccination. Front Immunol 2023;14:1196988. [PMID: 37545492 PMCID: PMC10401431 DOI: 10.3389/fimmu.2023.1196988] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2023] [Accepted: 06/29/2023] [Indexed: 08/08/2023] Open

Abstract

Introduction

The rapid evolution of SARS-CoV-2 has posed a challenge to long-lasting immunity against the novel virus. Apart from neutralizing function, binding antibodies induced by vaccination or infection play an important role in containing the infection.

Methods

To determine the proportion of wild-type (WT)-generated antibodies recognizant of more recent variants, plasma samples from either SARS-CoV-2 WT-infected (n = 336) or double-mRNA (Comirnaty)-vaccinated individuals (n = 354, age and sex matched to the convalescent group) were analyzed for binding antibody capacity against the S1 protein of the BA.1 omicron variant.

Results

Overall, 38.59% (95% CI, 37.01- 40.20) of WT-generated antibodies recognized Omicron BA.1 S1 protein [28.83% (95% CI, 26.73-30.91) after infection and 43.46% (95% CI, 41.61-45.31) after vaccination; p < 0.001]. Although the proportion of WT-generated binding and neutralizing antibodies also binding to BA.1 is substantially reduced, the avidity of the remaining antibodies against the Omicron variant was non-inferior to that of the ancestral virus: Omicron: 39.7% (95% CI: 38.1-41.3) as compared to the avidity to WT: 27.0% (95% CI, 25.5-28.4), respectively (p < 0.001). Furthermore, we noticed a modestly yet statistically significant higher avidity toward the Omicron epitopes among the vaccinated group (42.2%; 95% CI, 40.51-43.94) as compared to the convalescent counterparts (36.4%; 95% CI, 33.42-38.76) (p = 0.003), even after adjusting for antibody concentration.

Discussion

Our results suggest that an aspect of functional immunity against the novel strain was considerably retained after WT contact, speculatively counteracting the impact of immune evasion toward neutralization of the strain. Higher antibody levels and cross-binding capacity among vaccinated individuals suggest an advantage of repeated exposure in generating robust immunity.

Collapse

Serwanga J, Baine C, Mugaba S, Ankunda V, Auma BO, Oluka GK, Kato L, Kitabye I, Sembera J, Odoch G, Ejou P, Nalumansi A, Gombe B, Musenero M, Kaleebu P. Seroprevalence and durability of antibody responses to AstraZeneca vaccination in Ugandans with prior mild or asymptomatic COVID-19: implications for vaccine policy. Front Immunol 2023;14:1183983. [PMID: 37205095 PMCID: PMC10187141 DOI: 10.3389/fimmu.2023.1183983] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2023] [Accepted: 04/06/2023] [Indexed: 05/21/2023] Open

Abstract

Introduction

The duration and timing of immunity conferred by COVID-19 vaccination in sub-Saharan Africa are crucial for guiding pandemic policy interventions, but systematic data for this region is scarce. This study investigated the antibody response after AstraZeneca vaccination in COVID-19 convalescent Ugandans.

Methods

We recruited 86 participants with a previous rt-PCR-confirmed mild or asymptomatic COVID-19 infection and measured the prevalence and levels of spike-directed IgG, IgM, and IgA antibodies at baseline, 14 and 28 days after the first dose (priming), 14 days after the second dose (boosting), and at six- and nine-months post-priming. We also measured the prevalence and levels of nucleoprotein-directed antibodies to assess breakthrough infections.

Results

Within two weeks of priming, vaccination substantially increased the prevalence and concentrations of spike-directed antibodies (p < 0.0001, Wilcoxon signed rank test), with 97.0% and 66% of vaccinated individuals possessing S-IgG and S-IgA antibodies before administering the booster dose. S-IgM prevalence changed marginally after the initial vaccination and barely after the booster, consistent with an already primed immune system. However, we also observed a rise in nucleoprotein seroprevalence, indicative of breakthroughs six months after the initial vaccination.

Discussion

Our results suggest that vaccination of COVID-19 convalescent individuals with the AstraZeneca vaccine induces a robust and differential spike-directed antibody response. The data highlights the value of vaccination as an effective method for inducing immunity in previously infected individuals and the importance of administering two doses to maintain protective immunity. Monitoring anti-spike IgG and IgA when assessing vaccine-induced antibody responses is suggested for this population; assessing S-IgM will underestimate the response. The AstraZeneca vaccine is a valuable tool in the fight against COVID-19. Further research is needed to determine the durability of vaccine-induced immunity and the potential need for booster doses.

Collapse

Affiliation(s)

Jennifer Serwanga Pathogen Genomics, Phenotype, and Immunity Program, Medical Research Council, Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine, Uganda Research Unit, Entebbe, Uganda Department of Immunology, Uganda Virus Research Institute, Entebbe, Uganda
Claire Baine Department of Immunology, Uganda Virus Research Institute, Entebbe, Uganda
Susan Mugaba Pathogen Genomics, Phenotype, and Immunity Program, Medical Research Council, Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine, Uganda Research Unit, Entebbe, Uganda
Violet Ankunda Department of Immunology, Uganda Virus Research Institute, Entebbe, Uganda
Betty Oliver Auma Pathogen Genomics, Phenotype, and Immunity Program, Medical Research Council, Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine, Uganda Research Unit, Entebbe, Uganda
Gerald Kevin Oluka Pathogen Genomics, Phenotype, and Immunity Program, Medical Research Council, Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine, Uganda Research Unit, Entebbe, Uganda Department of Immunology, Uganda Virus Research Institute, Entebbe, Uganda
Laban Kato Pathogen Genomics, Phenotype, and Immunity Program, Medical Research Council, Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine, Uganda Research Unit, Entebbe, Uganda
Isaac Kitabye Pathogen Genomics, Phenotype, and Immunity Program, Medical Research Council, Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine, Uganda Research Unit, Entebbe, Uganda
Jackson Sembera Department of Immunology, Uganda Virus Research Institute, Entebbe, Uganda
Geoffrey Odoch Pathogen Genomics, Phenotype, and Immunity Program, Medical Research Council, Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine, Uganda Research Unit, Entebbe, Uganda
Peter Ejou Pathogen Genomics, Phenotype, and Immunity Program, Medical Research Council, Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine, Uganda Research Unit, Entebbe, Uganda
Amina Nalumansi Department of Immunology, Uganda Virus Research Institute, Entebbe, Uganda
Ben Gombe Pathogen Genomics, Phenotype, and Immunity Program, Medical Research Council, Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine, Uganda Research Unit, Entebbe, Uganda
Monica Musenero Science, Technology, and Innovation Secretariat, Office of the President, Government of Uganda, Kampala, Uganda
Pontiano Kaleebu Pathogen Genomics, Phenotype, and Immunity Program, Medical Research Council, Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine, Uganda Research Unit, Entebbe, Uganda Department of Immunology, Uganda Virus Research Institute, Entebbe, Uganda

Collapse

Zhang W, Liu S, Miao L, Fu A, Bao J, Zheng L, Li E, Yu J, Wang Y. Dynamics of CD4⁺ T-Cells and Neutralizing Antibody Responses to Three Consecutive Doses of Inactivated COVID-19 Vaccines in PLWH. Infect Drug Resist 2023;16:2695-2707. [PMID: 37168513 PMCID: PMC10166092 DOI: 10.2147/idr.s409147] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2023] [Accepted: 04/20/2023] [Indexed: 05/13/2023] Open

Abstract

Background

Comprehensive characterization of safety and immune responses to vaccines is crucial for the prevention and treatment of COVID-19 among people living with HIV (PLWH). This study aimed to investigate the dynamic changes in SARS-CoV-2-specific CD4⁺ T-cell subsets and neutralizing antibody after three consecutive doses of inactivated COVID-19 vaccines (BBIBP-CorV) among PLWH.

Methods

The blood samples were collected from 165 PLWH, including 66 PLWH in the 3-month interval between the second and third dose (cohort 1) and 99 PLWH in the 5-month interval (cohort 2). Blood collection for immunogenicity analysis was performed at 1-month post-2nd vaccination, pre-3rd vaccination, and within 2-month post-3rd vaccination. Wilcoxon matched-pairs signed-rank test was applied to compare the SARS-CoV-2-specific CD4⁺ T cell subsets and neutralizing antibody level at different time points. The relationship among CD4⁺ T-cells, Tregs subpopulations and SARS-CoV-2-specific neutralizing antibody level were evaluated with Spearman non-parametric correlation test.

Results

No serious adverse reactions were found among PLWH. After two-dose or three-dose inactivated COVID-19 vaccination, the absolute counts of CD4⁺ T-cells and Tregs subpopulations (CD4⁺CD25^HighCD127^Low Tregs, CD45RA⁺ rTregs and CD45RO⁺ eTregs) increased in two cohorts. Satisfactory SARS-CoV-2-specific neutralizing antibody responses to the third-dose vaccination were found in two cohorts, including significantly enhanced neutralizing antibody level and high neutralizing antibody seroconversion rate. In addition, SARS-CoV-2-specific neutralizing antibody level were positively associated with the absolute counts of CD4⁺ T-cells and Tregs subpopulations as well as the frequency of CD45RO⁺ eTregs in PLWH after three doses of vaccinations.

Conclusion

The three doses of inactivated COVID-19 vaccination were both safe and effective to increase SARS-CoV-2-specific CD4⁺ T-cells and neutralizing antibody in two PLWH cohorts with different inoculation intervals.

Collapse

Affiliation(s)

Wenhui Zhang Department of Infection, Affiliated Hangzhou Xixi Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China Department of Nursing, Affiliated Hangzhou Xixi Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China
Shourong Liu Department of Infection, Affiliated Hangzhou Xixi Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China
Liangbin Miao Institute of Hepatology and Epidemiology, Affiliated Hangzhou Xixi Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China
Ai Fu Institute of Hepatology and Epidemiology, Affiliated Hangzhou Xixi Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China
Jianfeng Bao Department of Hepatology, Affiliated Hangzhou Xixi Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China
Liping Zheng Department of Nursing, Affiliated Hangzhou Xixi Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China
Er Li Department of Nursing, Affiliated Hangzhou Xixi Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China
Jianhua Yu Department of Infection, Affiliated Hangzhou Xixi Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China Correspondence: Jianhua Yu, Department of Infection, Affiliated Hangzhou Xixi Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China, Email
Yi Wang Department of Infection, Affiliated Hangzhou Xixi Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China Institute of Hepatology and Epidemiology, Affiliated Hangzhou Xixi Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China Yi Wang, Institute of Hepatology and Epidemiology, Affiliated Hangzhou Xixi Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China, Email

Collapse

Dapporto F, Leonardi M, Trombetta CM, Semplici C, Piu P, Piccini G, Benincasa L, Marchi S, Andreano E, Lovreglio P, Buonvino N, Decaro N, Stufano A, Lorusso E, Bombardieri E, Ruello A, Viviani S, Rappuoli R, Molesti E, Manenti A, Montomoli E. The neutralizing response to SARS-CoV-2 Omicron variants BA.1 and BA.2 in COVID-19 patients and homologous and heterologous vaccinees. Hum Vaccin Immunother 2022;18:2129196. [PMID: 36269939 DOI: 10.1080/21645515.2022.2129196] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open

Affiliation(s)

Francesca Dapporto VisMederi srl, Siena, Italy
Margherita Leonardi VisMederi srl, Siena, Italy
Claudia Maria Trombetta VisMederi Research srl, Siena, Italy.,Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy
Claudia Semplici VisMederi srl, Siena, Italy
Pietro Piu VisMederi srl, Siena, Italy
Giulia Piccini VisMederi srl, Siena, Italy
Linda Benincasa VisMederi srl, Siena, Italy.,VisMederi Research srl, Siena, Italy
Serena Marchi Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy
Emanuele Andreano Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Siena, Italy
Piero Lovreglio Interdisciplinary Department of Medicine, Section of Occupational Medicine, University of Bari, Bari, Italy
Nicola Buonvino U.O.C. Penitentiary Medicine - Department of Territorial Care, Bari Local Health Authority, Bari, Italy
Nicola Decaro Department of Veterinary Medicine, University of Bari, Valenzano, Italy
Angela Stufano Interdisciplinary Department of Medicine, Section of Occupational Medicine, University of Bari, Bari, Italy
Eleonora Lorusso Department of Veterinary Medicine, University of Bari, Valenzano, Italy
Emilio Bombardieri Humanitas Gavazzeni, Bergamo, Italy
Antonella Ruello Humanitas Gavazzeni, Bergamo, Italy
Simonetta Viviani Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy
Rino Rappuoli Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Siena, Italy.,Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy
Eleonora Molesti VisMederi srl, Siena, Italy
Alessandro Manenti VisMederi srl, Siena, Italy
Emanuele Montomoli VisMederi srl, Siena, Italy.,VisMederi Research srl, Siena, Italy.,Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy

Collapse

Bauer G, Struck F, Staschik E, Maile J, Wochinz‐Richter K, Motz M, Soutschek E. Differential avidity determination of IgG directed towards the receptor-binding domain (RBD) of SARS-CoV-2 wild-type and its variants in one assay: Rational tool for the assessment of protective immunity. J Med Virol 2022;94:5294-5303. [PMID: 35851961 PMCID: PMC9349558 DOI: 10.1002/jmv.28006] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2022] [Revised: 07/02/2022] [Accepted: 07/14/2022] [Indexed: 12/15/2022]